Key Insights from CDMO Trends in Oral Solid Dosage
The first pills date back to roughly 1,500 BC, and whilst the pharmaceutical landscape continues to evolve, drug delivery via oral solid dosage (OSD) remains a dominant form due to the ease with which tablets are administered, patients’ familiarity with the dose form, and efficient manufacturing techniques. Even as other drug types - such as biologics - gain traction, OSD continues to be the standout performer in terms of cost-effectiveness, simple production processes, and enhanced long-term drug stability.
New Technologies Shaping the Industry
More recently, advancements in 3D printing and controlled-release technologies are providing new opportunities for innovation within the OSD segment but, these bring their own complexities too. For sponsors, finding and partnering with trusted CDMOs who are willing to manage all aspects of OSD manufacturing - from development through to production - is proving particularly advantageous for smaller, agile pharmaceutical companies who focus on niche diseases and patient populations.
Utilizing CDMOs provides a range of benefits too; cost reduction, accelerated timelines, and access to specialized expertise. Combine that with their capabilities to scale, manage risk, and offer global capabilities, and it quickly becomes clear why CDMOs are an invaluable resource to pharma companies that lack some or all the required internal capabilities.
Market Trends Driving CDMO Partnerships
With an evolution in the OSD drug market, CDMOs must invest in a broad array of technologies and maintain a highly skilled workforce to meet and attract pharmaceutical sponsors. CDMOs that specialize in dosage forms like controlled release, extended release, and targeted delivery are seeing high demand.
Over recent years, the rise of targeted therapeutic areas and orphan drug indications has led to smaller batch sizes. Service offerings under one provider - especially those with a single FDA site registration - are also pivotal to streamlining the drug development process.
Supply chain disruptions continue to threaten the industry, and OSD manufacturing is not immune. CDMOs must be able to demonstrate their ability to overcome challenges such as shortages of raw materials, transportation challenges, and geopolitical factors that can impact the reliable and timely supply of materials.
Reliable CDMO partnerships that can mitigate risks and ensure the continuity of drug manufacturing schedules will only grow more critical, with their ability to provide cutting-edge technologies, adaptable solutions, and global expertise, CDMOs stand at the forefront of pharmaceutical innovation.
For more, please find the original story source here.
